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a  b  s  t  r  a  c  t
A range  of  biopharmaceutical  products  are  used  to target  Vascular  Endothelial  Growth  Factor  (VEGF),
including  Eylea® (aflibercept,  AFL)  and Zaltrap® (ziv-aflibercept,  ziv-AFL).  The  first  is indicated  for  oph-
thalmological  diseases  such  as neovascular  (wet)  age-related  macular  degeneration,  while  the  second  is
used  in  the  treatment  of  metastatic  colorectal  cancer.  The  stability  of AFL  in prefilled  syringes  has  been
widely  studied;  however,  no  research  has  yet  been  done  on  the  stability  of  ziv-AFL  in  polyolefin  infu-
sion  bags.  Therefore,  the purpose  of  the  present  research  is to  evaluate  the  stability  of ziv-AFL  (Zaltrap®)
clinical  solutions  prepared  under  aseptic  conditions  in polyolefin  infusion  bags  at two  different  concen-
trations,  i.e. 4.0 and  0.6  mg/mL,  and  stored  refrigerated  in darkness  at 2−8 ◦C  for  14 days.  With  that  aim,
the  ziv-AFL  clinical  solutions  were  assessed  by analysing  changes  in  its physicochemical  and  functional
properties.  The  distribution  of  the  particulates  was  studied  over  a  range  of  0.001–10  m by  Dynamic
Light  Scattering  (DLS);  oligomers  were  analysed  by Size-Exclusion  High-Performance  Chromatography
with  Diode  Array  Detection  (SE/HLPC-DAD);  the  secondary  structure  of  the  protein  was  studied  by far
UV Circular  Dichroism  (CD)  and  the  tertiary  structure  by  Intrinsic  Tryptophan  Fluorescence  (IT-F)  and
Intrinsic  Protein  Fluorescence  (IP-F);  charge  variants  were  assessed  by  Strong  Cation  Exchange  Ultra-
High-Performance  Chromatography  with  UV  detection  (SCX/UHPLC-UV);  functionality  was  evaluated  by
ELISA  by  measuring  the biological  activity  as  manifested  in  the  extension  of  the  immunological  reaction
of  the  ziv-AFL  with  its  antigen  (VEGF).  Neither  aggregation  nor  oligomerization  were  detected  by  the
techniques  mentioned  above.  Secondary  and  tertiary  structures  remained  unchanged  over the  14-day
period,  as did  charge  variants.  The  functionality  observed  initially  was  maintained  along  time.  There-
fore,  it  could  be proposed  that  the  ziv-AFL  clinical  solutions  studied  showed  great  physicochemical  and
functional  stability  over  a period  of  two weeks,  regardless  of the  concentration,  i.e.  4  or  0.6  mg/mL.







Ziv-aflibercept (Ziv-AFL) is a Vascular Endothelial Growth Fac-
tor (VEGF)-trap [1] that consists of the VEGF receptor extracellular
binding domains 1 and 2 fused to the Fc portion of a human IgG1.
Ziv-AFL acts as a soluble decoy receptor that binds to circulating
VEGF A, VEGF B and Placental Growth Factor (PlGF). When it traps
these ligands, it prevents the endogenous ligands from activating
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heir respective receptors and thus blocks signaling. It is a recombi-
ant Fc-fusion protein produced in a Chinese Hamster Ovary (CHO)
-1 mammalian expression system by recombinant DNA  tech-
ology. In combination with irinotecan/5-fluorouracil/folinic acid
FOLFIRI) chemotherapy, it is indicated in adults with metastatic
olorectal cancer (MCRC) that is resistant to or has progressed after
n oxaliplatin-containing regimen [2]. There are other pharmaceu-
ical products on the market that target VEGF in the treatment
f different common chorioretinal vascular diseases, such as neo-
ascular age-related macular degeneration (nAMD) [3], diabetic
acular edema (DME) and retinal vein occlusion (RVO) [4]. These
nclude aflibercept (AFL) (Eylea®; Regeneron, Tarrytown, NY and
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Bayer Healthcare, Leverkusen, Germany), ranibizumab (Lucentis®;
Genentech, South San Francisco, CA and Roche, Basel, Switzerland)
and bevacizumab (Avastin®; Genentech, South San Francisco, CA
and Roche, Basel, Switzerland).
The prefix “ziv” is used to differentiate the AFL in Zaltrap® from
the AFL in Eylea®; both medicines share the same active substance
but have different formulations, and therefore different indica-
tions. Although AFL is manufactured by Regeneron Pharmaceuticals
Inc, different pharmaceutical companies are responsible for batch
release: Sanofi Aventis for Zaltrap® and Bayer AG for Eylea®.
The manufacturer of Zaltrap® indicates that this drug product
is chemically and physically stable for 24 h at 2−8 ◦C and for 8 h at
25 ◦C once diluted in infusion bags and assuming that dilution has
been performed under controlled and validated aseptic conditions
[2]. Despite these indications, it recommends, due to microbiolog-
ical issues, that the solutions prepared for infusion should be used
immediately. Any decision to extend this recommended period
must be taken by the user and it will be their sole responsibility [2].
Manufacturers usually establish short maximum stability periods
for biotechnological and biological medicines due to their fragile
nature and possible risks to patient safety [5]. Stability studies on
biopharmaceuticals that reproduce hospital storage conditions are
essential [6–8] as they guarantee the reuse of the daily surplus
in hospital pharmacies including the pharmaceutical preparations
not administered due to medical treatment interruption. As an
example, A. Kannan et al. [9] studied the in-use interfacial stability
of monoclonal antibody (mAb) formulations diluted in saline i.v.
bags to evaluate the mAb  aggregation propensity in saline medium
0.9 % NaCl in comparison with low ionic strength formulation
buffer; results indicated higher tendency to aggregate in the saline
medium. Since the approval of AFL and ziv-AFL [10,11], several sta-
bility studies have been carried out, the majority on AFL rather than
on ziv-AFL. These studies assessed their stability in compounded
syringes and most sought to evaluate the continuing functionality
of the drug over time.
In 2015, A.M. Mansour et al. [12] proposed that ziv-AFL main-
tained its functionality for 4 weeks after being compounded in
polycarbonate syringes and stored refrigerated. Similarly, in 2017,
M. Schicht et al. [13] evaluated the functionality of AFL compounded
in syringes over 120 h stored at 4 ◦C by means of cell proliferation
assays and VEGF-ELISA, evaluating inhibition of cell proliferation
and binding to VEGF respectively. In contrast to the specifications
included in the summary of product characteristics for Eylea® [14],
they demonstrated that AFL maintained its biological function over
the five-day study period. For their part, S. Cao et al. [15] reported
the functional stability of AFL when placed in plastic syringes and
stored refrigerated for up to 4 weeks by determining half maximal
inhibitory concentration (IC50) performing competitive binding
assays against PlGF.
In 2018, J. De Lima Farah et al. [16] demonstrated the stabil-
ity of AFL and ziv-AFL when compounded in tuberculin-type 1-mL
plastic syringes and stored at 4 ◦C and -8 ◦C for 28 days. This
was done by evaluating the mass recovered from the syringes and
checking functional properties in ELISA experiments. M.S. Sivertsen
et al. [17] published a stability study in which AFL was com-
pounded in prefilled plastic syringes and stored refrigerated over 4
weeks. The results obtained from a set of suitable analytical tech-
niques such as dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE), size exclusion chromatography (SEC), antihuman Fc
ELISA, FcRn binding ELISA, surface plasmon resonance (SPR) and
differential scanning fluorimetry (DSF) confirmed the quality, sta-
bility and antigen/Fc binding properties of the protein over the
4-week period. These authors also developed a novel method
for compounding and storage of three anti-VEGF drugs (includ-
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ame analytical techniques as in the previous study [17], they
emonstrated that AFL maintained its physical stability and func-
ionality over a period of 7 days when stored at 4 ◦C in dark
onditions.
Recently, D.P. Han et al. [19] compounded AFL in polycarbon-
te syringes and stored them at 4 ◦C and -20 ◦C for 14 days. They
emonstrated the physical and functional stability of AFL at these
onditions using ELISA and DLS techniques. M.R. Moreno et al.
20] undertook a more complete study, evaluating AFL stability
ver 30 days under physiological conditions and when formu-
ated in a drug delivery system (DDS) based on microparticles.
tability was checked using SEC, circular dichroism (CD), fluo-
escence spectroscopy (FS), SDS-PAGE and ELISA. These authors
roposed the physicochemical and functional stability of AFL at
7 ◦C and at different pH values ranging from 4.5–8.5 over 30
ays. They also demonstrated the stability of AFL after simulat-
ng a water/oil (w/o) emulsification process, a first step towards
rotein entrapment, using different organic solvents such as tri-
cetin.
Although all these studies assure that AFL and ziv-AFL are stable
hen stored in prefilled syringes under the right conditions, no
esearch has yet been conducted into the stability of ziv-AFL diluted
n NaCl (0.9 %) and stored in polyolefin bags. Up until now, interest
as focused on assessing the stability of AFL in prefilled syringes
ue to the high cost of this treatment. However, ziv-AFL is also
ery expensive compared to traditional treatments and its stability
n real hospital preparations should be evaluated so as to provide
cientific evidence on which to base the complex decisions that
ust be taken regarding the reuse of this product.
In this research, a comprehensive set of previously validated
hysicochemical and functional methods [21,22] were applied to
ssess the stability over time (two weeks) of clinical solutions
f ziv-AFL. The main critical attributes (CQA) of proteins such as
articulates, oligomers, aggregates, secondary and tertiary struc-
ures, charge variants and binding to VEGF were investigated. These
ttributes need to be strictly monitored during process develop-
ent and manufacturing in order to ensure product quality [23]
nd must also be controlled in real conditions of use in stability
tudies.
. Materials and methods
.1. Materials and reagents
4 mL  fresh vials containing 100 mg  of ziv-AFL (Zaltrap®, Sanofi
ventis) were kindly supplied by the San Cecilio University Hospital
Granada, Spain).
Nunc maxisorp microplates were supplied by Labclinic S.A.
Barcelona, Spain). Anti-human IgG (whole molecule)-peroxidase
ntibody from rabbit, O-Phenylenediamine Dihydrochloride -as
the sigmafast opd”- (OPD), Vascular Endothelial Growth Factor
VEGF) produced in E.coli, sodium phosphate monobasic mono-
ydrate were supplied by Sigma Aldrich (Madrid, Spain). Sodium
arbonate, sodium hydrogen carbonate, sodium chloride, potas-
ium chloride, disodium phosphate monohydrate and potassium
hosphate monobasic were purchased from Panreac (Barcelona,
pain).Tween 20 was  supplied by Fluka Chemika (Madrid, Spain).
kimmed milk powder “La Asturiana” (Oviedo, Spain) was  acquired
n the local market. Size exclusion column standard calibration
Advance BioSEC 300 Å protein standard) was supplied by Agi-
ent technologies (California, USA). Reverse-osmosis-quality water
urified (≥18 M/cm)  with a Milli-RO plus Milli-Q station from
illipore Corp. (Madrid, Spain) was  used throughout the study.
everse-osmosis-quality water was purified with a Milli-Qstation

















































J. Hermosilla, R. Pérez-Robles, A. Salmerón-García et al. 
2.2. Stability study
The stability of ziv-AFL was assessed using an ad hoc work
procedure that was mainly based on the ICH Q6B international
guideline [24]. To this end, we assessed a range of physicochemical
and biological attributes in the ziv-AFL solutions. The physico-
chemical attributes were tested using a combined set of analytical
techniques, and functionality was assessed using a biochemical
approach. Table 1 in Supplementary Data indicates the method-
ology used in this research.
2.2.1. Ziv-AFL samples
Two different ziv-AFL concentrations were evaluated to cover
the range commonly used in real clinical practice: 4 mg/mL  (inter-
mediate concentration) and 0.6 mg/mL  (low concentration).
The medicinal product Zaltrap® contains 25 mg/mL  of ziv-AFL
in a concentrated solution for dilution for infusion [2]. Two doses
of the medicine are currently available: a) vials containing 100 mg
of the active substance in 4 mL  of water for injection and b) vials
containing 200 mg  in 8 mL.  In this study, the lower dose, i.e. vials
containing 100 mg  of ziv-AFL (batch number: 7F008C/ expiration
date: 10–2020) was used to prepare the diluted solutions for infu-
sion following the instructions set out in the technical report [2].
In this way, several vials of ziv-AFL 25 mg/mL  were used to pre-
pare 50 mL  of 4.0 and 0.6 mg/mL  ziv-AFL diluted solutions in NaCl
0.9 % under validated aseptic conditions using a laminar flow cabi-
net (Aura Vertical S.D.4, Bio Air Instruments, Italy). This procedure
was conducted according to the Hospital Pharmacy routine pro-
tocol: appropriate syringes were used to withdraw from the vials
the volume of medicine needed to reach the desired concentrations
(i.e. 4.0 mg/mL  and 0.6 mg/mL) in the 50 mL  NaCl 0.9 % polyolefin
infusion bags (Baxter, Spain, batch number: 19E05E3S/ expiration
date: 07–2020), from which the whole contents had previously
been extracted with 50 mL  BD Plastipak syringes (batch num-
ber: 1707229/ expiration date: 06-2022). The necessary volumes
of medicine and solution were then added to the bags to prepare
the final concentrations. Due to the limits on obtaining samples
of the medicine, we prepared two independent replicates for each
storage container as accepted for this situation [8]. Therefore, two
bags of each concentration were prepared.
2.2.2. Methodology applied
The stability-indicating nature of all the methods used in this
study was validated by accelerated degradation studies performed
in a recently published work about ziv-AFL [21,22], in which
the following stresses were applied: 12 h light irradiation, expo-
sure to high temperature (60 ◦C and 70 ◦C), subjection to several
freeze/thaw cycles, pH variation of the drug product, dilution in a
hypertonic 1.5 M NaCl solution and 6 M guanidine HCl denaturing
solution.
2.2.3. Stability studies over time
4 and 0.6 mg/mL  ziv-AFL clinical solutions, stored in polyolefin
bags, were analysed for a period of 14 days in order to assess their
stability over time when stored refrigerated (2−8 ◦C) in darkness. In
all cases, Day 0, the day when the clinical solutions were prepared,
was established as the control or reference day, and the results from
all subsequent experiences were compared to this day.
The stability of the two clinical solutions, i.e. 4.0 and 0.6 mg/mL,
was studied by using the analytical techniques included in Table 1
(Supplementary Data), over a period of 14 days. The solutions were
analysed on: Day 0 (preparation of the clinical solutions), Day 1,
Day 2, Day 7or 8, Day 10 or 11 and Day 14. All the techniques were
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Visual inspections were carried out prior to experimentation in
rder to detect the formation of large aggregates, turbidity, sus-
ended particles, colour changes and gas formation. To this end,
amples were visually inspected using the naked eye.
.3.2. Far UV circular dichroism (CD)
Ziv-AFL secondary structures were studied using a JASCO J-815
pectropolarimeter (JASCO, Tokyo, Japan). The method was opti-
ized at a concentration of 0.25 mg/mL  of ziv-AFL. Each spectrum
as  registered with a scanning speed of 20 nm/min, every 0.2 nm
nd a total of 5 accumulations were averaged between 200 and
50 nm.  A 1 mm quartz cuvette was  used throughout the stability
tudy. Temperature was  controlled at a constant 20 ◦C. Raw spectra
ere smoothed using the Means-Movement method with a convo-
ution width of 25. All the spectra were visually inspected in order
o detect changes in the secondary structures of ziv-AFL. The con-
ent of the secondary structure was  estimated using the Dichroweb
ebsite [25].
.3.3. Intrinsic tryptophan fluorescence spectroscopy (IT-FS)
For Emission, spectra measurements were carried out on a Cary
clipse spectrofluorometer (Agilent, U.S.A) and recorded from 300
o 400 nm with the excitation wavelength set to 298 nm.  The tem-
erature of the samples was kept at 20 ◦C using a thermostatically
ontrolled cell holder. A total of 5 spectral accumulations were
veraged per spectrum. The excitation and emission slits were set
o 5 nm for the 4 mg/mL  bag samples and to 10 nm for the 0.6
g/mL  bag samples. The blank of the appropriate solvent without
he antibody was  measured and then subtracted from each sam-
le spectrum. Each spectrum was  converted mathematically to a






here i is the wavelength and fi the corresponding intensity
.3.4. Intrinsic protein fluorescence spectroscopy (IP-FS)
Emission spectra measurements were carried out on a Cary
clipse spectrofluorometer (Agilent, U.S.A) from 300 to 400 nm,
ith the excitation wavelength set to 280 nm. The temperature of
he samples was kept at 20 ◦C using a thermostatically controlled
ell holder. A total of 5 spectral accumulations were averaged per
pectrum. Excitation and emission slits were set to 5 nm.  The blank
f the appropriate solvent without the antibody was measured and
hen subtracted from each sample spectrum. Each spectrum was
onverted into a number (Spectral Centre of Mass, C.M.) from 300
o 400 nm using Equation 1.
.3.5. Dynamic light scattering
DLS records were obtained on a Zetasizer Nano-ZS90 Malvern
UK). Particle size distribution was  determined on 1 mL of sample
olume using 10 mm spectrophotometry disposable cuvettes. Each
ample record was a result of 100 accumulated readings taken at a
hermostatically controlled temperature of 20 ◦C and with a time
cquisition of 5 s per reading. The average hydrodynamic diameter
HD), polydispersity index (PDI), Z-average and size distribution by
olume and intensity were compared and discussed for all the bag
amples over the 14-day study period.
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2.3.6. Size-exclusion high-performance chromatography with
diode array detection (SE/HLPC-DAD)
The analysis was performed by liquid chromatography using an
Agilent 1100 chromatograph equipped with a quaternary pump,
degasser, autosampler, column oven and photodiode array detector
(Agilent Technologies, USA).
Samples were evaluated in a SEC-5 column (300Bio, Agilent
Technologies, USA) in which temperature was set at 25 ◦C. The
flow rate was 0.35 mL/min and the mobile phase was composed
of 150 mM of phosphate buffer pH 7.0. An isocratic elution mode
was applied for 17 min. The UV–vis spectra were recorded between
190 nm and 400 nm with a data point every 0.5 nm. Chromatograms
were registered at 214 nm with a reference band at 390 nm.  This
method was previously reported [21].
The column was calibrated in order to establish the relation-
ship between the molecular weight and the retention time of the
Fc-protein. The calibration kit (Agilent, USA) was  composed of 5
proteins: thyroglobulin (670 kDa), -globulin (150 kDa), ovalbumin
(45 kDa), myoglobin (17 kDa) and angiotensin II (1 kDa).
2.3.7. Strong cation exchange ultra-high-Performance
chromatography (SCX/UHPLC-UV) charge variant analysis
This analysis was conducted using a proper analytical plat-
form (Thermo Scientific, Waltham, MA,  USA). The chromatographic
separation was  carried out using a Dionex UltiMate 3000 chro-
matograph (Thermo Scientific, Waltham, MA,  USA), equipped with
two ternary pumps, a degasser, an autosampler, a thermostatted
column compartment, and a multiple-wavelength detector (MWD-
3000Vis-UV detector). The method was previously reported [22]
and developed to detect changes in the ziv-AFL charge variant pro-
file.
Chromatographic separation was carried out in a MabPac SCX-
10 RS 2.1 mm × 50 mm column with 5 m particles (Thermo Fisher
Scientific, Waltham, MA,  USA). The column temperature was 30 ◦C
and the flow rate was 0.4 mL/min. The eluent system was  composed
of 10 mM of Na2HPO4 at pH 5.0 (mobile phase A) and 10 mM  of
Na2HPO4 and 300 mM of NaCl at pH 10.0 (mobile phase B). The
column was equilibrated with 10 % of mobile phase B for 9 min. A
linear gradient was applied when the percentage of mobile phase
B was increased from 10 % to 40 % in 15 min. The percentage of
mobile phase B was then increased again to 100 % in 1 min  and
was maintained at this level for 4 min. The initial conditions were
restored in 1 min. The UV chromatograms were registered at 214
nm [22].
2.3.8. ELISA
An indirect, non-competitive ELISA based on the specific inter-
action of ziv-AFL with VEGF was applied to check for ziv-AFL
biological activity, and was then used to study the diluted ziv-AFL
clinical solutions stored in the bags over a period of 14 days. This
method was adapted from our previous works [21,26]. In brief,
96-well Maxisorp immune plates were sensitized with VEGF by
incubation overnight (18 h) at 4 ◦C adding 100 L/well of 0.25
g/mL VEGF diluted in 0.1 M carbonate buffer solution (pH 9.6).
The plates were washed (VASHER RT-2600C microplate washer,
Comecta, Abrera, Barcelona) four times with PBS-Tween® 20 (pH
7.4 containing 0.3 % (v/v) Tween® 20). They were then treated with
100 l of the blocking buffer (PBS pH 7.4 containing skimmed milk
2 % (w/v)) per well for 2 h at 37 ◦C to eliminate nonspecific absorp-
tions. Each plate was washed again and filled with 100 L of ziv-AFL
control samples and samples from the bags appropriately diluted
in 0.1 M carbonate buffer pH 9.6 at several concentrations ranging
from 1 ng/mL to 100 g/mL. After incubating for 45 min  at 37 ◦C,
the plates were washed four times with PBS and incubated again
with 100 l/well of a solution of 10 g/mL of peroxidase-labelled




ig. 1. Representative Circular Dichroism (CD) spectra of ziv-AFL (Zaltrap®) solu-
ions  stored in polyolefin infusion bags over the 14-day stability study period: A) 4
g/mL  bag; B) 0.6 mg/mL  bag.
ion pH 9.6 for 30 min at 37 ◦C. After washing four times with PBS,
00 L of the substrate solution (OPD) was added to each well and
ncubated for 20 min  in darkness at room temperature (25 ◦C). The
eaction was stopped by adding 50 L of 1 M sulfuric acid solu-
ion. The absorbance was recorded at 450 nm and 620 nm,  and the
nalytical signal was  the difference between the two  absorbance
alues (TECAN SUNRISETM microplate absorbance reader for 96-
ell plates connected to a computer loaded with XFluor4 software,
ecan, Austria, GMB). On each test day, the absorbance of the ziv-




All the solutions remained clear without turbidity through-
ut the stability study, indicating that no visual aggregates had
ormed. The solutions also remained colourless throughout the
tudy period.
.2. Circular dichroism spectroscopy (CD)The two  bag replicate samples for each concentration stud-
ed showed practically identical spectral features. Therefore, Fig. 1
hows the ziv-AFL representative spectra (from one of the two
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Table  1
CD spectral features of ziv-AFL representative bags samples over the stability study period: 4 and 0.6 mg/mL.
4 mg/mL  Spectral minima Wavelength (CD = 0) Minima Ellipticity 0.6 mg/mL  Spectral minima Wavelength (CD = 0) Minima Ellipticity
Day 0 217.4 207.4 −9.3 Day 0 217.8 207.2 −9.0
Day  1 217.4 207.0 −9.4 Day 1 217.4 207.1 −9.1
Day  2 217.2 207.1 −9.1 Day 2 217.6 207.3 −9.0
Day  7 217.4 207.0 −9.3 Day 7 217.2 207.1 −8.7
Day  11 217.4 207.2 −8.9 Day 11 217.6 207.3 −8.5
Day  14 217.0 207.2 −9.0 Day 14 217.0 207.0 −8.8
CD (Circular Dichroism).
Table 2
Representative fluorescence spectral centre of mass (C.M) values of the ziv-AFL bags samples over the stability study.
C.M. (at exc 298 nm,  IT-FS)
C.M. Day 0 Day 1 Day 2 Day 7 Day 10 Day 14
4  mg/mL Bag 346 346 346 346 346 –
0.6  mg/mL  Bag 345.8 345.7 345.8 345.8 345.8 –
C.M.  (at exc 280 nm,  IP-FS)
C.M. Day 0 Day 1 Day 2 Day 7 Day 10 Day 14




































0.6  mg/mL  Bag 343.9 343.9 
C.M (Centre of Mass); exc (excitation wavelength); IT-FS (Intrinsic Tryptophan Flu
replicates) for the bag samples from Day 0 to Day 14 for 4.0 and 0.6
mg/mL  bag samples. These representative spectra are described in
more detail in Table 1 via their spectral features. As can be seen
in Fig. 1, the ziv-AFL CD spectra are identical for the 4.0 and 0.6
mg/mL  bag samples. The spectral shape remains unchanged over
the 14 days. A more detailed analysis of these spectral features
of ziv-AFL is shown in Table 1, including the CD spectrum mini-
mum  and the wavelength at ellipticity 0. Ziv-AFL has a minimum
at 217−218 nm and a wavelength (ellipticity = 0) at 207–207.5 nm.
These values were corroborated to remain unchanged in all the
bag replicate samples throughout the study, so indicating that no
changes had taken place in the secondary structure of the ziv-AFL
in any of the bag samples studied. An estimation of the secondary
structure content can be found in the Supplementary Data (Tables
2 and 3). These results indicate that secondary structure of ziv-AFL
remained unchanged over the 14-day test period for both concen-
trations assessed.
3.3. Intrinsic tryptophan fluorescence spectroscopy (IT-FS)
The tertiary structure of ziv-AFL in the solutions at 4.0 and 0.6
mg/mL  was analysed by IT-FS. Representative results of the fluo-
rescence C.M. from one of the bag replicates for each concentration
studied are shown in Table 2 since the standard deviation between
the two replicates were close to 0 value. These results in Table 2
indicate that this CQA remained unchanged throughout the test
period (10 days). The representative C.M. value of the IT-F spectra
for the 4 mg/mL  ziv-AFL bag samples was 346 nm at Day 0; this
value remained constant over the 10-day test period for two repli-
cates. For the two bag samples of 0.6 mg/mL  ziv-AFL, this value was
345.8 at Day 0 and also remained unchanged over the 10 days of
study.
3.4. Intrinsic protein fluorescence (IP-FS)
The fact that the tertiary structure of the ziv-AFL in the clini-
cal solutions remained unchanged was also corroborated similarly
by IP-FS. The representative C.M. of the spectra from the 4 mg/mL
and the 0.6 mg/mL  ziv-AFL solution bag samples was 343.9 at Day






.9 344.0 343.9 –
nce Spectra); IP-FS (Intrinsic Protein Fluorescence Spectra).
.5. Dynamic light scattering (DLS)
Representative results for particulates of up to 10 m in the
olutions over time are shown in Fig. 2 (volume size distribution
raphs) and in Table 3 (Z-average and PDI values). For Z-average
nd HD results, statistical comparison was performed on the results
rom the two bag replicates for each concentration at a confidence
evel of 95 %, corroborating there was  not statistical differences
etween the two values compared. Therefore, the results show
ext are from one of these two bag replicates as representa-
ive.
In Fig. 2 there are two size distribution graphs (A and B) for
he 4 and 0.6 mg/mL  ziv-AFL bag samples; in both cases, a single
articulate population was detected and was attributed to protein
onomers with an average HD of 11 ± 3.4 nm and 11.3 ± 3.1 nm
espectively. These values were maintained over the 14 days with
o significant differences as can be corroborated in graphs A and B
f Fig. 2.
As regards the size distribution by intensity shown in Supple-
entary Data (Fig. 2); for 4 mg/mL  bag samples, the only peak that
ontributed to the intensity was the protein monomer population.
he only exception was on Day 0, in which a peak was detected
t 2.5 m,  although this contributed just 0.1 % of total volume,
nd was therefore considered an artefact, and was  not observed in
he other bag replicate. For 0.6 mg/mL  bag samples, intensity was
aused mainly by the peak associated with the protein monomer
opulation, with other peaks contributing just 0.1 %, and therefore
eing considered as artefacts, and similarly occurs in the other bag
eplicate.
The Z-average values for the ziv-AFL 4 mg/mL solutions (Table 3)
ndicated that no aggregation process was  taking place as the values
emained similar throughout the 14-day period in all the samples.
esults for the most diluted solution at 0.6 mg/mL  were discarded
s the concentration was  too low to enable us to interpret this
arameter. As regards the PDI value (Table 3), this ranged between
.1−0.2 for ziv-AFL 4 mg/mL  bag samples and between 0.1−0.5
or 0.6 mg/mL  bag samples. These results indicated that there was
o significant dispersion in the size of the population, as it was
lways < 0.7 [27] for all samples. For 0.6 mg/mL  samples the higher
DI value obtained in some of the samples (up to 0.5) was also
ttributed to this higher dilution of the ziv-AFL sample, which could
J. Hermosilla, R. Pérez-Robles, A. Salmerón-García et al. Journal of Pharmaceutical and Biomedical Analysis 203 (2021) 114209
Fig. 2. Representative size distribution by volume of 4 mg/mL  A) and 0.6 mg/m
Table 3
Z-average and polydispersity index (PDI) values for the representative ziv-AFL bags
samples over the stability study.
Z-average PDI
Day 4 mg/mL bag 4 mg/mL  bag 0.6 mg/mL  bag
0  14 ± 5 0.25 0.32
1  11 ± 6 0.10 0.46
2  12 ± 5 0.15 0.28
7  12 ± 5 0.15 0.28



















14  12 ± 5 0.18 0.22
PDI (Polydispersity Index).
make the results not interpretable, not only for the Z-average but
also for the PDI value.
3.6. Size-Exclusion chromatography (SE/HLPC-DAD)
The chromatographic profile for the oligomers was  checked
using (SE)HPLC-DAD, so as to detect possible incipient aggrega-
tion in the ziv-AFL bags (4 and 0.6 mg/mL). Representative control
chromatograms (those registered at Day 0) are shown in Fig. 3. Both




L  B) ziv-AFL (Zaltrap®) solutions stored in polyolefin bags over 14 days.
his case two replicates of each bag) were characterised by two
eaks: one small peak eluting at 6.7 ± 0.2 min  and another, the
ain peak, eluting at 7.57 ± 0.1 min. The first peak was attributed
o the presence of the natural dimer (representing 2% of the total
rea for ziv-AFL in the chromatogram) and the second peak was
ttributed to the monomer in accordance with previous works [21]
n which this issue was investigated in depth.
Fig. 3 shows the UV-SEC chromatograms corresponding to rep-
esentative replicates of ziv-AFL in the stability study, showing the
esults at Day 0 (control), 7 and 14. These chromatographic profiles
emained unchanged over the study period, in terms of both the
lution time and the area under the peak, as can be seen in Fig. 3 for
he two concentrations of ziv-AFL studied. The value of the area of
he peaks corresponding to the dimer and the monomer remained
onstant over the period of study, as did the proportion between
hem. No new aggregations or fragmentations were detected on
ny of the test days. The analysis of all chromatographic profiles
learly indicates high stability and a high degree of similarity in the
olutions over the study period.The concentration of the ziv-AFL bags solutions was estimated
sing the chromatographic area under the peak and this was con-
inued throughout the study period. The concentration estimated

















Fig. 3. Representative size exclusion high-performance chromatography with diod
in  polyolefin bags over the 14-day study period: A) 4 mg/mL  bag. B) 0.6 mg/mL  bag
was always at around 4 ± 0.27 mg/mL  and 0.6 ± 0.20 mg/mL. No
significant changes were observed, indicating that the concentra-
tions of ziv-AFL remained constant over the 14-day study period,
with no adsorption on the wall of the container or degradation.
3.7. Strong cation exchange ultra-high-Performance
chromatography ((SCX)UHPLC/UV)
The variant profile is one of the most frequently analysed
characteristics in protein stability studies and is related with the
presence or absence of different posttranslational modifications.
In this paper, the charge variant profile was assessed using the
(SCX)UHPLC/UV method, which had previously demonstrated its
ability to detect changes when ziv-AFL samples were submitted to
different physical stresses [22].
This method was applied to monitor the ziv-AFL charge vari-
ants in the clinical solutions at 4 and 0.6 mg/mL during storage in
polyolefin bags for 14 days. Fig. 4 shows the (SCX)UHPLC/UV chro-
matograms for representative replicates of samples from ziv-AFL
bags at Day 0, 7 and 14. These chromatograms have very similar






y detection (SE-HLPC-DAD) chromatograms of Ziv-AFL (Zaltrap®) solutions stored
ppear. The retention times are also similar over time for all the
amples (9.52 ± 0.03 min  and 9.59 ± 0.05 min for ziv-AFL 4 mg/mL
nd 0.6 mg/mL  bag samples respectively, estimated using results
rom the two bag replicates, and in this case two  replicates of each
ag). A more detailed discussion of this particular charge variant
rofile of ziv-AFL can be found in [22]. The fact that no changes
ere detected in the different charge variants of ziv-AFL indicates
hat no chemical changes had taken place in the clinical solutions.
.8. ELISA
The ELISA method was  developed and validated ad hoc for the
uantification of the specific interaction between ziv-AFL and VEGF,
s a mean of checking the functionality of this Fc-fusion protein
21]. Fig. 5 shows the results of the present stability study, in
hich Ziv-AFL-VEGF binding curves are represented over the 14-
ay study period for the two concentrations studied (including the
esults from the two bags). In the graphs, the absorbance ± SD is
epresented as a function of the concentration of ziv-AFL. Control
amples (fresh samples prepared “there and then”) were used for
omparison purposes each check day and their results are shown in













samples over the 14 days of the study. Two  clinical concentrationsFig. 4. Representative strong cation exchange high-performance chromatography w
stored  in polyolefin bags over the 14-day study period: (A) 4 mg/mL  bag. (B) 0.6 mg
blue; for ziv-AFL 4 mg/mL  bag samples the results are displayed in
red while the 0.6 mg/mL  samples appear in green. Broadly speak-
ing, there is no significant decay in the absorbance of the samples
analysed with respect to the control samples at any concentration
(4 or 0.6 mg/mL  ziv-AFL) or at any time during the study period (14
days), therefore confirming the functional stability of these clinical
solutions for at least 14 days. As can be seen in Fig. 5, the behaviour
of the immunoreaction ziv-AFL-VEGF was very similar to the con-
trol samples, as indicated by the similar tendency in the graph,
with no significant differences (see error bars) between the par-
ticular experimental concentrations used to build the graph. Only
two experimental points (indicated in Fig. 5 with an “*” in the 0.6
mg/mL  bag sample on Day 1 and in the 4 mg/mL bag sample on
Day 14) showed significant decay in the absorbance, which was
attributed to an unexpected error while manipulating the sam-
ples. Nevertheless, these two experimental points do not affect





raviolet detection (SCX/UHPLC-UV) chromatograms of Ziv-AFL (Zaltrap®) solutions
ag.
f the other experimental points and the tendency of the graphs
learly indicated similar ziv-AFL-VEGF interaction in the control
fresh) samples and in the bag samples at concentrations of 4 and
.6 mg/mL.
. Discussion
A set of previously validated analytical methodologies [21,22]
ere selected for a comprehensive analysis of the stability of the
omplex Fc-fusion protein ziv-AFL in real hospital conditions of use
 clinical solutions placed in polyolefin infusion bags – stored refrig-
rated at 2−8 ◦C for two  weeks. In this paper, analytical similarity
as assessed in terms of the values of the main CQA of the ziv-AFLf ziv-AFL were evaluated: one at an intermediate level of clini-
al concentration (4 mg/mL) and the other at a lower level (0.6
g/mL).





























Fig. 5. Ziv-AFL (Zaltrap®)-VEGF non-competitive indirect ELISA graphs: absorbance
study  period. Control samples (blue line); 4 mg/mL  bag (red line) and 0.6 mg/mL  b
reader  is referred to the web version of this article).
Aggregation was evaluated using three analytical methods: a) by
analysing oligomers by SEC, b) by analysing larger soluble partic-
ulate populations up to 10 m by DLS and c) by visual inspection.
The results indicated that no changes had taken place in the ini-
tial particulate populations in the solutions and therefore that the
clinical solutions remained unchanged. The SE-chromatographic
profile indicates that oligomerization of ziv-AFL did not occur in
any of the bag solutions over the 14-day study period. The partic-
ulate profile obtained from DLS indicated that aggregation did not
take place in either of the bag solutions over the check period. The
solutions remained clear in all visual checks. Therefore, no insta-
bility due to aggregation occurred in the 14-day study period in
either of the solutions (4 or 0.6 mg/  mL), and the ratio between the
natural ziv-AFL dimers and monomers remained the same through-
out (around 2 % dimers/98 % monomers), an important finding
given that in previous research on ziv-AFL it was  demonstrated
that the main degradation pathway in this therapeutic Fc-fusion
protein was dimerization and the formation of high molecular
weight aggregates (non-natural) [21]. Nonetheless, our results indi-
cate that the controlled storage conditions applied in this study
prevented aggregation.
The secondary structure of the protein was assessed by CD spec-
troscopy, and it was deduced that in both clinical solutions of
ziv-AFL (4 and 0.6 mg/mL) the secondary structure remained stable
over the 14-day period. The ziv-AFL CD spectra for the two sam-
ples remained unaltered as did the ellipticity. These results indicate
that no -amyloid aggregates were formed during the study period,
as in recent research on the same protein we observed, using CD
spectroscopy, a clear increase in the negative band associated with
the same aggregation process [21]. Moreover, the estimation of the
content of secondary structure using Dichroweb [25] indicated a
high percentage of  sheet and random coil, which remained unal-






sented as a function of ziv-AFL concentration (0.001-100 g/mL) over the 14-day
reen line) (For interpretation of the references to colour in this figure legend, the
The tertiary structure of ziv-AFL was  assessed by estimating the
ryptophan fluorescence spectral centre of mass. This remained
onstant over the 10 days tested in both ziv-AFL bag solutions.
his confirms that the tryptophan environment in the protein con-
ormation was unaltered. This finding, together with the results
btained from the intrinsic protein fluorescence test, allowed us
o conclude that protein conformation in these solutions remained
naltered over the 10-day period.
Ziv-AFL is a very complex glycosylated Fc-fusion protein, which
as a protein structure with a molecular weight of 97 kDa. Accord-
ng to the manufacturer, the glycosylation part increases the weight
f the molecule by 15 % (up to 115 kDa) [21]. This complex gly-
an structure makes it difficult to develop analytical methods that
an properly identify the different AFL charge variants [28]. How-
ver, the charge variant profile is a CQA that should be included
n any study of stability. In previous research, a (SCX)UHPLC-UV
ethod was  shown to be capable of detecting changes in the charge
ariant profile of ziv-AFL, although it did not manage to iden-
ify or separate the different charge variants [28]. We  therefore
ecided to use this method here to track changes in the charge vari-
nt profile of ziv-AFL in the clinical solutions, so as to assess the
tability of these solutions over time. As these profiles remained
onstant, with high levels of similarity amongst all the samples
egardless of the concentrations studied (4 or 0.6 mg/mL), this indi-
ates that over the 14 days no chemical changes took place that
ight have affected the charge profile of ziv-AFL in these clinical
olutions.
Finally, if we  take into account the functionality of ziv-AFL mea-
ured as the capacity of the protein to bind to its target, i.e the VEGF;
ur results show that the Fc-fusion protein maintained its function-
lity over the 14-day study period, with no evidence of functional
oss in either clinical solution. This is also coherent with the results
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ity of the other quality attributes had been demonstrated), in that
a decrease in functionality is usually accompanied by a conforma-
tional change.
Our results demonstrate high physicochemical and functional
stability of ziv-AFL during the 14-day stability study. The values
for the CQA of the ziv-AFL samples were very similar to those for
the control samples, i.e. the samples analysed immediately after
preparation. The analytical results were also highly similar for the
two concentrations tested, i.e. 4 mg/mL  and 0.6 mg/mL.
5. Conclusions
In this study we analysed two concentrations (an intermediate
concentration of 4 mg/mL  in 0.9 % NaCl and a low concentration
of 0.6 mg/mL  in 0.9 % NaCl) of ziv-AFL clinical solutions prepared
aseptically in polyolefin infusion bags and stored refrigerated in
darkness. A specific set of analytical techniques were used to eval-
uate the main physicochemical CQA in addition to monitoring the
functional integrity of the Fc-fusion protein over the 14-day test
period by assessing its capacity to bind to its target, the VEGF. These
tests revealed very similar results over the two-week period indi-
cating a high degree of stability in both solutions. All the methods
and strategies applied in this study had previously been validated to
confirm their ability to detect changes in the structure or function-
ality of ziv-AFL. No changes were detected in the CQA that might
impair the efficacy and safety of the medicine. These results will
encourage hospital pharmacists to reuse Zaltrap® when stored in
the conditions studied here.
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